Subscribe

Shitanshu Uppal

GOG 3073/ENGOT-72: Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA)

Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.

Publications Update # 105

Making magic with Brad Meltzer, venous thromboembolism during ambulatory chemotherapy in endometrial cancer (including the NCCN and ASCO guidelines), IMRT in vulvar cancer, and hypofractionated adjuvant radiation in cervical cancer patients.

Publications Update # 104

New Episode of GYOEDU Podcast, ASCO abstracts - Challenge trial, TRUST trial, cytoxan+Avastin vs. cytoxan+Avastin+Pembrolizumab, Menopause management with Elinzatenant, and a review of cancer of unknown primary site.

Publications Update # 103

MIS in cervical cancer in SHAPE trial-eligible patients, pragmatic testing with IHC rather to replace the PROMISE algorithm and two questions about PFT and vulvar cancer groin management.

Congratulations, and No Newsletter this week

SOLO-3: Olaparib vs. Chemotherapy in PSROC

Olaparib significantly improved PFS and ORR over nonplatinum chemotherapy, though no OS benefit was observed in the overall population. In patients with ≥3 prior therapies, chemotherapy had more favorable OS.

Question of the Day 05-21-25

Which of the following best characterizes the drug-to-antibody ratio (DAR)

Publications Update # 102

Happiest country, PDS Vs. NACT a fresh perspective (video), fear in the OR, and a vulvar cancer review article worth reading.

Vulvar Cancer Quiz

Publications Update # 101

Interview with Isabel Allende, updated tips for staying organized for the board prep, p53 staining in endometrial cancer, secondary debulking in platinum-sensitive ovarian cancer, Epigenetic MLH1 and outcomes